SS-31 (Elamipretide) vs BNP (B-type Natriuretic Peptide)

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

SS-31 (Elamipretide)

SS-31, also known as Elamipretide or Bendavia, is a mitochondria-targeted tetrapeptide. It has been studied extensively for mitochondrial diseases, heart failure, and age-related decline in mitochondrial function.

Full details →

BNP (B-type Natriuretic Peptide)

BNP is a cardiac neurohormone released primarily by ventricles in response to volume/pressure overload. It's a major biomarker for heart failure and has therapeutic applications as nesiritide.

Full details →

Side-by-Side Comparison

AspectSS-31 (Elamipretide)BNP (B-type Natriuretic Peptide)
MechanismConcentrates in the inner mitochondrial membrane where it binds to cardiolipin, stabilizing electron transport chain function, reducing reactive oxygen species, and improving ATP production efficiency.Similar to ANP - activates NPR-A receptors to produce vasodilation, natriuresis, and RAAS suppression. Released in response to ventricular wall stress.
Typical DosageClinical trials have used IV infusions of 0.25mg/kg for acute conditions. Subcutaneous dosing protocols for research use typically range from 1-5mg daily.Nesiritide (recombinant BNP): 2mcg/kg IV bolus followed by 0.01mcg/kg/min continuous infusion for acute decompensated heart failure.
AdministrationCan be administered IV or subcutaneously. Most clinical research has used IV administration for cardiac conditions.Intravenous administration only. Used in acute care settings for heart failure. BNP levels also used diagnostically.
Side EffectsGenerally well-tolerated. Clinical trials reported injection site reactions and occasional headache.Hypotension (common and dose-limiting), headache, nausea, and potential renal function worsening in some patients.
Best For

What They Have in Common

Both SS-31 (Elamipretide) and BNP (B-type Natriuretic Peptide) are commonly used for:

Key Differences

Unique to SS-31 (Elamipretide):

Ready to Learn More?